Enterprise Value
234.7M
Cash
47.75M
Avg Qtr Burn
-10.93M
Short % of Float
1.92%
Insider Ownership
3.46%
Institutional Own.
31.63%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Avasopasem Manganese (GC4419) Details Head and neck cancer, Cancer Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
Rucosopasem Details Pancreatic cancer, Cancer | Phase 2b Data readout | |
Rucosopasem Details Cancer, Non-small cell lung carcinoma | Phase 2 Data readout | |
Avasopasem Manganese (GC4419) Details Lung cancer, Esophagitis | Phase 2 Update | |
Avasopasem Manganese (GC4419) Details Infectious disease, COVID-19 | Failed Discontinued |